- Home
- WT vs ARVN Comparison
WT vs ARVN Comparison
Compare WT & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WT
- ARVN
- Stock Information
- Founded
- WT 1985
- ARVN 2015
- Country
- WT United States
- ARVN United States
- Employees
- WT N/A
- ARVN N/A
- Industry
- WT Investment Bankers/Brokers/Service
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- WT Finance
- ARVN Health Care
- Exchange
- WT Nasdaq
- ARVN Nasdaq
- Market Cap
- WT 1.6B
- ARVN 1.8B
- IPO Year
- WT N/A
- ARVN 2018
- Fundamental
- Price
- WT $10.62
- ARVN $18.48
- Analyst Decision
- WT Buy
- ARVN Strong Buy
- Analyst Count
- WT 9
- ARVN 13
- Target Price
- WT $12.08
- ARVN $63.00
- AVG Volume (30 Days)
- WT 1.7M
- ARVN 967.8K
- Earning Date
- WT 01-31-2025
- ARVN 10-30-2024
- Dividend Yield
- WT 1.13%
- ARVN N/A
- EPS Growth
- WT N/A
- ARVN N/A
- EPS
- WT 0.31
- ARVN N/A
- Revenue
- WT $407,884,000.00
- ARVN $161,100,000.00
- Revenue This Year
- WT $26.44
- ARVN $237.44
- Revenue Next Year
- WT $8.55
- ARVN N/A
- P/E Ratio
- WT $33.92
- ARVN N/A
- Revenue Growth
- WT 23.04
- ARVN 1.07
- 52 Week Low
- WT $6.57
- ARVN $17.37
- 52 Week High
- WT $12.45
- ARVN $53.08
- Technical
- Relative Strength Index (RSI)
- WT 39.35
- ARVN 32.78
- Support Level
- WT $10.48
- ARVN $17.37
- Resistance Level
- WT $11.91
- ARVN $19.21
- Average True Range (ATR)
- WT 0.38
- ARVN 1.64
- MACD
- WT -0.15
- ARVN -0.59
- Stochastic Oscillator
- WT 23.60
- ARVN 11.80
About WT WisdomTree Inc.
WisdomTree Inc is a financial innovator, offering a well-diversified suite of exchange-traded products (ETPs), models, and solutions. It offers a broad range of ETFs and exchange-traded products (ETPs). The firm also engages in developing next-generation digital products and structures, including digital funds and tokenized assets, as well as its blockchain-native digital wallet, WisdomTree Prime.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.